Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+repurposed+drugs

12 Results

Sort By:

Orally Administered Metformin to Treat Hair Loss in Central Centrifugal Cicatricial Alopecia

Value Proposition:· Potential first-in-class treatment for CCCA, a condition impacting a substantial proportion of Black women. · Repurposes metformin, a well-studied and naturally available compound with an established safety profile and a low cost of manufacturing.· Oral administration as a simple, self-managed treatment. Unmet Need:Central...

Published: 5/14/2024 | Inventor(s): Crystal Aguh

Keywords(s):

Category(s): Clinical and Disease Specializations > Dermatology > Alopecia, Clinical and Disease Specializations > Dermatology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Nanocrystal-based Suspension Formulation of Nintedanib for Inhaled Treatment of Silicosis and other Fibrotic Lung Diseases

Value Proposition· Intranasal inhaled formulation of nintedanib (NTB) allows for more targeted dosing.· Minimizes risk of systemic adverse events in the lung.· Enhances drug retention in the lung for local treatment via inhalation.· Formulation allows for long-term storage and remote shipping.· Surface-stabilized with...

Published: 5/10/2024 | Inventor(s): Jung Soo Suk, Luisa Andrade da Silva, Patricia Rocco, Marcelo Morales

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Adjunct Therapy with Psychedelics

Unmet NeedImpairment of neuronal function in adults is challenging to treat. No pharmaceutical interventions have shown promise in restoring cognitive and motor function after acute neurologic injury, as is the case in recovery following transient ischemic attack or stroke. Treatment of neurologic, cognitive, and motor impairment in the mature brain...

Published: 5/10/2024 | Inventor(s): Gul Dolen, John Krakauer, Romain Nardou, Steven Zeiler, Junia de Deus

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Stroke, Clinical and Disease Specializations > Neurology > Cerebral Ischemia

Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis

Unmet NeedAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life expectancy from diagnosis to mortality is between 2-5 years....

Published: 5/9/2024 | Inventor(s): Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis

Pharmacological Intervention of the Arachidonic Acid Pathway to Cure Amyotrophic Lateral Sclerosis

Unmet NeedAmyotrophic Lateral Sclerosis (ALS) affects as many as 30,000 people in the United States alone, with 5,000 new cases diagnosed every year. ALS is a fatal neuromuscular disease that is characterized by a progressive degeneration of the motor nerve cells and spinal cord. There are only two drugs approved by FDA for the treatment of ALS, and...

Published: 5/9/2024 | Inventor(s): Gabsang Lee, Hyungjin Eoh, Hojae Lee, Thomas Lloyd, Nicholas Maragakis

Keywords(s): Amyotrophic Lateral Sclerosis, CNS and Neurological Disorders, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Locoregional Chemotherapy for Liver Cancers

Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...

Published: 5/9/2024 | Inventor(s): Florin Selaru, Ling Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer

Discovery of Novel Compounds that Enhance Enteric Nervous System Function

Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...

Published: 5/9/2024 | Inventor(s): David Hackam, Peng Lu, Chhinder Sodhi

Keywords(s): Agonists/Promoters, Disease Indication, Inflammatory Disorders, Necrotizing Enterocolitis (NEC), Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Alpha particle formulations for treatment of solid tumors

Unmet NeedHepatocellular carcinoma (HCC) is the fifth most common cancer type worldwide and a leading cause of cancer related deaths. HCC is clinically silent in its early stages, leading to diagnosis at more advanced stages when only non-surgical, palliative treatment is available. One treatment option for advanced HCC is intra-arterial therapy and...

Published: 5/9/2024 | Inventor(s): Jessie Nedrow, Eleni Liapi

Keywords(s): Biologics, Cancers, Disease Indication, Liver Cancer, Non-novel, Predicted Novelty, Radioisotope Therapy, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

Drugs Promoting Retinal Rod Photoreceptor Survival

Unmet NeedRetinitis pigmentosa (RP) is a genetic disorder that can result from more than 60 mutations that cause severe rod photoreceptor degeneration and death. It is estimated to affect 1 in 4000 people worldwide, with approximately 100,000 cases in the United States. Symptoms begin in childhood with a loss of night vision, and eventually RP leads...

Published: 5/9/2024 | Inventor(s): Jeff Mumm

Keywords(s): Disease Indication, Eye Disorders, Retinitis pigmentosa, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules

Therapies to Accelerate Resolution of Acute Lung Inflammation

Acute respiratory distress syndrome (ARDS) is a devastating inflammatory lung disease for which there are no effective targeted therapies. In experimental models of acute lung inflammation and injury, regulatory T cells (Tregs) orchestrate a pro-repair program; Tregs themselves are highly dependent on epigenetic mechanisms such as DNA hypomethylation. ...

Published: 5/9/2024 | Inventor(s): Franco D'alessio, Landon King, Benjamin Singer, Neil Aggarwal

Keywords(s): Acute Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome (ARDS), Antagonists/Inhibitors, Chemotherapy, Disease Indication, Immunotherapy, Lung Disorders, Non-novel, Predicted Novelty, Repurposed, Single, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases > Acute Respiratory Distress Syndrome, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Respiratory Diseases, Technology Classifications > Therapeutic Modalities > Repurposed Drugs

1 2